Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory large B-cell lymphoma (r/r LBCL) across multiple locations in China, marking the second indication for its self-developed CD19-targeted CAR-T therapy.
Contents
Regulatory & Commercial Milestone
| Attribute | Details |
|---|---|
| Company | Juventas Cell Therapy Ltd |
| Product | Inaticabtagene autoleucel (CD19-targeted CAR-T) |
| Launch Date | 04 Dec 2025 |
| New Indication | Relapsed or refractory large B-cell lymphoma (r/r LBCL) |
| Geographic Coverage | Multiple locations across China |
Development & Approval Timeline
| Date | Milestone | Indication |
|---|---|---|
| Nov 2023 | First NMPA approval | Adult r/r B-cell acute lymphoblastic leukemia (r/r B-ALL) |
| 28 Nov 2025 | Second NMPA approval | r/r LBCL |
| 04 Dec 2025 | Commercial launch | r/r LBCL (multi-location rollout) |
Product Profile & Mechanism
- Technology: Self-developed CD19-targeted chimeric antigen receptor (CAR) T-cell therapy
- Mechanism: Genetically engineered T-cells expressing CD19-binding CAR to eliminate malignant B-cells
- Manufacturing: Autologous cell therapy produced in Juventas’ GMP facilities
- Administration: Single intravenous infusion following lymphodepletion chemotherapy
Market Context & Competitive Landscape
| Market Parameter | Value/Insight |
|---|---|
| China LBCL Incidence | ~25,000 new cases annually; ~40% become r/r |
| CAR‑T Market Size (China) | Projected ¥8 billion by 2028 |
| Competition | Axicabtagene ciloleucel (Fosun Kite), Tisagenlecleucel (Novartis) |
| Juventas Differentiation | First domestic CAR-T with dual hematologic malignancy approvals |
| Pricing | Estimated ¥1.2-1.5 million per treatment; potential for NRDL inclusion |
Strategic Outlook & Commercial Implications
- Multi-Location Launch: Demonstrates robust commercial infrastructure and supply chain readiness
- Portfolio Expansion: Dual indications (B-ALL + LBCL) maximize manufacturing facility utilization
- Market Penetration: LBCL indication addresses larger patient population vs. B-ALL
- Revenue Impact: Analysts project ¥500-800 million peak sales from LBCL indication by 2028
- Pipeline Value: Validates platform technology for potential future CAR-T candidates in solid tumors
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Juventas’ commercial launch execution, market penetration, and revenue projections for inaticabtagene autoleucel. Actual results may differ due to manufacturing capacity, competitive dynamics, and reimbursement uncertainties.-Fineline Info & Tech
